Biosimilars: An Overview for Clinicians

In this module, Robert M. Rifkin, MD, FACP, and Kenneth G. Saag, MD, MSc, provide their expert answers to your frequently asked questions about biosimilars and their application in clinical practice.

Robert M. Rifkin, MD, FACP Kenneth G. Saag, MD, MSc Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: March 9, 2017 Expired: March 8, 2018

In this module, Sanjiv S. Agarwala, MD, and Alan J. Kivitz, MD, CPI, expand on the application of biosimilars to clinical practice by answering questions submitted by learners.

Sanjiv S. Agarwala, MD Alan J. Kivitz, MD, CPI Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: May 16, 2017 Expired: May 15, 2018

In this downloadable slideset, Sanjiv S. Agarwala, MD; Alan J. Kivitz, MD, CPI; Robert M. Rifkin, MD, FACP; and Kenneth G. Saag, MD, MSc, provide an overview of biosimilars, a new therapeutic class of drugs.

Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.

Kenneth G. Saag, MD, MSc Released: March 13, 2017

The role of biosimilars in the setting of IBD is growing. Here’s my take on some of the key things you need to consider when using these agents.

David T. Rubin, MD Released: June 6, 2017